Baird raises target for Cencora stock to USD 373.00
π Baird raised Cencora's price target from USD 370.00 to USD 373.00 while maintaining an Outperform rating.
π° Fiscal Q3 revenue reached USD 84.80 billion, marking a 5.10% year-over-year increase.
π Adjusted operating income grew by 17.00% and adjusted EPS increased by 12.00% in the third quarter.
π Management raised full-year fiscal 2026 EPS guidance to USD 17.75-17.95 from the prior range of USD 17.70-17.90.
π The company is scheduled to report fiscal fourth-quarter results on November 4, 2026.
π’ Cencora operates a large pharmaceutical distribution center utilizing trucks and forklifts for daily logistics.
Bullish Signals
- Baird raised the price target from USD 370.00 to USD 373.00, signaling continued analyst confidence in the stock's valuation.
- Fiscal third-quarter revenue grew by 5.10% year over year to reach USD 84.80 billion, demonstrating solid top-line growth.
- Adjusted operating income expanded significantly by 17.00%, indicating strong operational leverage and margin improvement.
- Adjusted earnings per share increased by 12.00% in the quarter, reflecting successful cost management or pricing power.
- Management raised full-year fiscal 2026 EPS guidance to USD 17.75-17.95, exceeding previous expectations and validating business momentum.
Full Analysis
Baird Capital raised its price target for Cencora Inc. (COR) from USD 370.00 to USD 373.00 on October 12, 2026, maintaining an Outperform rating. The analyst firm cited the company's strong fiscal third-quarter performance as a key driver for the valuation adjustment, providing fresh upside potential ahead of the upcoming fourth-quarter earnings release scheduled for November 4, 2026.
Cencora reported robust financial results for the quarter ended June 30, 2026, with fiscal revenue reaching USD 84.80 billion, representing a 5.10% year-over-year increase. Adjusted operating income surged by 17.00%, while adjusted earnings per share climbed 12.00%, reflecting improved operational efficiency and margin expansion within the medical distribution sector.
Following the strong quarterly results, Cencora management raised its full-year fiscal 2026 adjusted earnings-per-share guidance to a range of USD 17.75-17.95 from the previous estimate of USD 17.70-17.90. This upward revision signals confidence in sustained demand across its US and international healthcare solutions businesses, positioning the stock favorably relative to its current trading price.